Michel Vounatsos (Credit: World Economic Forum/Ciaran McCrickard)
Biogen bets $60M upfront that a new antisense candidate from Ionis can one-up Spinraza
As Biogen stares down an impending patent cliff for its spinal muscular atrophy blockbuster Spinraza, it’s betting $60 million that a new antisense oligonucleotide from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
